- Home
- STHO vs ACRV Comparison
STHO vs ACRV Comparison
Compare STHO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- ACRV
- Stock Information
- Founded
- STHO N/A
- ACRV 2018
- Country
- STHO United States
- ACRV United States
- Employees
- STHO N/A
- ACRV N/A
- Industry
- STHO Real Estate
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- STHO Real Estate
- ACRV Health Care
- Exchange
- STHO Nasdaq
- ACRV Nasdaq
- Market Cap
- STHO 120.0M
- ACRV 170.3M
- IPO Year
- STHO N/A
- ACRV 2022
- Fundamental
- Price
- STHO $9.01
- ACRV $5.65
- Analyst Decision
- STHO
- ACRV Strong Buy
- Analyst Count
- STHO 0
- ACRV 5
- Target Price
- STHO N/A
- ACRV $22.40
- AVG Volume (30 Days)
- STHO 95.2K
- ACRV 50.9K
- Earning Date
- STHO 02-25-2025
- ACRV 11-13-2024
- Dividend Yield
- STHO N/A
- ACRV N/A
- EPS Growth
- STHO N/A
- ACRV N/A
- EPS
- STHO 6.15
- ACRV N/A
- Revenue
- STHO $117,752,000.00
- ACRV N/A
- Revenue This Year
- STHO N/A
- ACRV N/A
- Revenue Next Year
- STHO N/A
- ACRV N/A
- P/E Ratio
- STHO $1.47
- ACRV N/A
- Revenue Growth
- STHO 13.35
- ACRV N/A
- 52 Week Low
- STHO $8.26
- ACRV $3.19
- 52 Week High
- STHO $14.50
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- STHO 37.20
- ACRV 41.71
- Support Level
- STHO $8.85
- ACRV $5.36
- Resistance Level
- STHO $9.08
- ACRV $6.00
- Average True Range (ATR)
- STHO 0.27
- ACRV 0.52
- MACD
- STHO 0.07
- ACRV -0.01
- Stochastic Oscillator
- STHO 46.58
- ACRV 17.74
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.